
usd may pm et
summari global medic devic manufactur oper segment cardiac vascular
minim invas therapi restor therapi diabet
price-to-earnings oper ep
risk assess reflect exposur intens
competit area medic equip market
typic character short product life cycl
price pressur threat new market entrant
howev think potenti neg off-set
mani competit advantag scale
oper sale forc product breadth
aug ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
may stock trade
anticip fy sale declin
billion follow growth fy
billion follow growth
fy near term expect mdt
result pressur elev spend
weaker revenu strong dollar howev
believ return
pre-pandem growth level fourth
quarter apr fy
although product approv timelin mdt
vast pipelin mostli remain track
far expect revenu acceler impact
product launch delay
pandem mdt key product
launch includ next-gener tavr
valv evolut micra av
transcathet pace system highli
long run expect organ growth
also driven mdt strong posit
emerg market grew
constant currenc basi fy fy
signific presenc emerg
market china latin america
appear promis emerg market
account revenu fy
fy fy
find share trade fy
ep estim underappreci
investor despit expect
pandemic-driven weak fy result
think well posit emerg
crisi stronger sever
sheet allow offens enabl
short- long-term market share captur
like high demand
divers product portfolio global footprint
cater well increasingli health-consci
world origin expect launch
platform key futur growth driver fy
howev pandem like push back
time launch
risk opinion target price includ
poor execut growth opportun
intern extern weak new product
pressur custom delay
issu robot program
target price base
fy ep april estim
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice presid
global oper
corpor overview lead manufactur develop market medic
devic therapi compani report total net sale fiscal year apr billion
broken follow oper segment cardiac vascular group billion
minim invas technolog group billion restor therapi group billion
cardiac vascular group compris cardiac rhythm heart failur crhf diseas
manag divis coronari structur heart divis aortic peripher venou divis
chrf divis develop manufactur market product diagnosi treatment
manag heart rhythm disord heart failur princip product servic offer
implant cardiac resynchron therapi devic atrial fibril ablat product
coronari structur heart divis includ therapi treat coronari arteri diseas heart valv
disord product coronari stent replac heart valv aortic peripher
venou divis compris comprehens line product therapi treat aortic diseas
includ product endovascular stent graft system peripher drug coat balloon
well peripher vascular diseas venou diseas
minim invas therapi group consist surgic innov divis
market advanc gener surgic product includ surgic stapl devic vessel seal
instrument wound closur electrosurgeri product hernia mechan devic mesh implant well
gynecolog product therapi treat diseas condit typic exclus
address surgeon respiratori gastrointestin renal divis develop manufactur
market product emerg field minim invas gastrointestin diagnost therapi
respiratori monitor airway manag ventil therapi treatment renal
restor therapi group made spine brain therapi specialti therapi pain
therapi divis spine divis develop manufactur market comprehens line
medic devic implant use treatment spine musculoskelet system includ
biolog solut orthoped dental market brain therapi divis develop manufactur
market integr portfolio devic therapi treatment neurolog disord
diseas well surgic technolog design improv precis workflow neuro
procedur specialti therapi divis develop manufactur market product therapi
treat diseas ear nose throat ent help control system overact bladder
non-obstruct urinari retent chronic fecal incontin pain therapi divis develop
manufactur market spinal cord stimul system implant drug infus system
chronic pain well intervent product
diabet group develop manufactur market product servic manag
type type ii diabet princip product servic offer group includ insulin pump
minim system continu glucos monitor system therapi manag
softwar help patient health care provid manag diabet treatment
competit landscap compet therapeut diagnost medic market
countri throughout world substanti exposur market
fy revenu came non-u develop market came emerg market
one largest medic devic compani domin presenc mani
medic devic market high switch cost custom recent
environ manag care econom motiv custom consolid among health care
provid increas competit declin reimburs rate increasingli requir
compet basi price
robot compani develop robot guidanc system billion juli sold
patient deep vein thrombosi nutrit insuffici busi
billion mdt last major acquisit covidien plc januari billion januari
quarter achiev million synergi commit relat acquisit
financi trend revenu grew year-over-year billion fy april
compar five-year compound annual growth rate compound-annual-growth-rate adjust earn per share grew
year-over-year fy per share compar five-year compound-annual-growth-rate april
net debt total capit ratio cash flow oper billion
fy billion billion achiev fy fy respect
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc may technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neg
recess concern although
medic devic sub-industri
histor defens recess resist
nonetheless expect near-term result
wors recent year despit neg
outlook think medic devic compani
fare much better compani
industri health care essenti
peopl expect
neg impact global procedur volum
procedur volum could quickli return
worst diseas impact pass
continu achiev robust organ growth
 mid-to-high single-digit revenu growth
driven new product grow
emerg market exposur howev expect
revenu neg impact
basi point result
mean anticip organ growth
low-single-digit
long run gener see posit
fundament trend medic devic
demand cost-effect value-bas health
care age popul rise outlay
result steadi flow
innov product revenu growth
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much commentari
around introduct mdr reason
believ new regul could
neg impact industri exampl
juli submit letter
world trade organ request
mdr ivdr delay three year also
novemb european medic devic
trade associ critic slow
piecem implement new
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
prior concern expect
industri earn rise low-double-digit
percentag driven sale new product
command higher margin expect
industri earn rise mid-single-digit
percentag origin project
industri oper ebit margin
estim margin
think margin
like flat year-over-year
year date march health
equip sub-index declin
vs declin
composit index health
increas valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep buy opinion share medtron plc
rais target base multipl
ep lift multipl reflect promis
upcom product launch grow exposur robot jul-q ep
vs beat estim rais fy apr ep
apr-q sale increas constant currenc cc basi
driven cc growth emerg market cc basi cardiac
restor therapi group grew diabet group grew
divis except diabet group outperform expect
diabet growth outsid grew strong clip
busi declin mid-singl digit competit challeng difficult
comp month host demonstr highli anticip
pm et cfra reiter buy opinion share medtron plc
lower target base multipl
ep multipl high-end
five-year rang encourag pipelin new
product apr-q ep vs beat estim lower
fy apr ep initi fy ep
apr-q sale increas organ basi driven
constant currenc cc growth emerg market cc
basi cardiac vascular group grew minim invas therapi
group grew restor therapi group grew diabet group
grew fy expect back half stronger headwind
anniversari numer product launch ramp continu anticip
fy launch surgic robot despit expect expenditur new
product launch believ achiev least basi point
cc oper margin expans fy /kevin huang cfa
analyst research note compani news
et cfra lift opinion share medtron plc strong buy
buy lower target multipl
newli initi fy apr ep estim apr-q ep vs
fell short consensu expect stronger-than-expect
headwind lower fy ep estim
reflect pandem potenti impact despit expect
pandemic-driven weak fy result think well posit
emerg crisi stronger sever reason includ
mdt strong balanc sheet allow offens enabl
short- long-term market share captur mdt grow remot
monitor capabl like high demand mdt
divers product portfolio global footprint cater well increasingli
health-consci world near term elev spend weaker revenu
strong dollar pressur result expect return
pre-pandem growth level fourth quarter apr fy /kevin
et cfra keep buy opinion share medtron plc
rais target base multipl
ep although jan-q ep vs
exceed estim quarterli revenu billion fell
million short consensu primarili curb custom spend ahead
product launch cardiac vascular group cvg
restor therapi group rtg mdt oper margin drove
quarter ep beat compani adjust oper margin
expand basi point due enterpris optim effort rais
fy apr ep factori china begin
start manag refrain quantifi impact
april quarter expect updat later quarter
anticip lower procedur growth due hospit overutil
china repres mdt busi like
stronger impact suppli chain disrupt /kevin huang cfa
et cfra maintain buy opinion share medtron plc
rais target base multipl
ep multipl
three-year rang reflect compani numer upcom product launch
grow exposur robot oct-q ep vs surpass
estim lift fy apr ep fy
ep sale grew yoy organ
expect led emerg market growth organ basi
cardiac vascular group grew minim invas therapi group grew
restor therapi group grew diabet group grew
expect growth acceler fiscal fy launch
mani new product although gross margin yoy primarili due
unfavor foreign exchang impact basi point bp partial due
china tariff oper margin improv bp yoy strong improv
sg /kevin huang cfa
pm et cfra maintain buy opinion share medtron plc
lift target price base
multipl ep estim rais
valuat reflect increas confid futur robot offer
yesterday sep host investor day highlight
develop initi offer soft-tissu robot-assist surgeri ra
market long domin
target launch two year european launch slightli
year ra offer featur upgrad univers mean
suit multipl type surgeri includ open surgeri mobil
tower open-design surgeon consol hd visual mobil
modular robot arm given world-wide surgeri market estim
penetr ra solut think well-thought-out
offer long runway growth /kevin huang cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share
declin usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
